Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oryzon GenomicsORYZF 33 Equity-to-Asset is 0.85 as of Jun. 2026, which is 12% above its 10-year median of 0.76. GuruFocus rates ORYZF with a GF Score™ of 33/100. Among 1,415 Biotechnology companies, Oryzon Genomics ranks better than 72.3% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Oryzon Genomics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $137.90 Mil. Oryzon Genomics's Total Assets for the quarter that ended in Jun. 2026 was $162.00 Mil.
The historical rank and industry rank for Oryzon Genomics's Equity-to-Asset or its related term are showing as below:
ORYZF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.41 Med: 0.76 Max: 0.85
Current: 0.85
During the past 12 years, the highest Equity to Asset Ratio of Oryzon Genomics was 0.85. The lowest was 0.41. And the median was 0.76.
ORYZF's Equity-to-Asset is ranked better than 72.3% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs ORYZF: 0.85
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Oryzon Genomics Equity-to-Asset Related Terms
Oryzon Genomics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Oryzon Genomics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORYZF vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Oryzon Genomics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oryzon Genomics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oryzon Genomics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Oryzon Genomics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Oryzon Genomics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oryzon Genomics (ORYZF) has a Equity-to-Asset of 0.85 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Oryzon Genomics and its competitors. This is 12% above median its historical median of 0.76. Over the past decade, Oryzon Genomics' Equity-to-Asset has ranged from 0.41 to 0.85. According to the industry distribution chart, Oryzon Genomics ranks #392 out of 1415 companies in the Biotechnology industry, placing it in the top 27.7%.
Is Oryzon Genomics' Equity-to-Asset too high?
Oryzon Genomics' current Equity-to-Asset of 0.85 is 12% above median its 10-year median of 0.76. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 0.85. The Biotechnology industry median Equity-to-Asset is 0.68. Oryzon Genomics' value of 0.85 is 25% above this industry median. Based on the distribution chart, Oryzon Genomics ranks #392 out of 1415 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oryzon Genomics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oryzon Genomics ranks #392 out of 1415 companies for Equity-to-Asset. This puts Oryzon Genomics in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Oryzon Genomics' value of 0.85 is 25% above this benchmark. Historically, Oryzon Genomics' own Equity-to-Asset has ranged from 0.41 to 0.85 over the past decade. While the company's 10-year median is 0.76 vs. the industry median of 0.68, Oryzon Genomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oryzon Genomics's current Equity-to-Asset of 0.85 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Oryzon Genomics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oryzon Genomics's current Equity-to-Asset is 0.85, which is 12% above median its own 10-year median of 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (ORYZF) has a current Equity-to-Asset of 0.85. The current Equity-to-Asset is 0.85, which is 12% above median its 10-year median of 0.76 and 25% above the Biotechnology industry median of 0.68. Oryzon Genomics' overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Oryzon Genomics (ORYZF), the current Equity-to-Asset is 0.85 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
33GF Score
Get the complete analysis for ORYZF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORYZF has been successfully added to your 
